Spur Capital Partners

Our community has funded more than 500 portfolio companies across all stages and sectors, with an emphasis on enterprise, life sciences, consumer, and frontier technology. WE INVEST IN THE BEST FOUNDERS: We invest up to $250k in talented Founders around the world. YOUR PARTNERS FROM START TO FINISH: We’re focused on Founders that have an exit in mind from the start. FOUNDERS HELPING FOUNDERS: We’ve been Founders so we know the challenge you face and have your back. Early Capital is Just The Beginning Our portfolio of early stage investments spans industries, markets, and countries. We work with all kinds of founders to get them that early capital, but we don’t stop there. Raising early capital is difficult, but once attained a founder has to set the foundations for scale and further fundraising which is much harder. JVP and its community are there as resources to help founders beyond that early capital. We know that capital isn’t enough. A first raise is just the beginning, and we use our industry knowledge and expertise to guide early stage companies past the initial investment and through the challenges of first hires, go to market strategy, developing strong intellectual property and scalability. We are founders ourselves, and understand the journey to profitability and exit. We combine our management expertise with rigorous quantitative analysis to guide our founders and their companies on the path to global impact.

AN Venture Partners is a venture capital fund investing in biotech. We aim to build blockbuster biotech companies primarily focusing on science from Japan. AN Ventures was founded with support from the Japanese government and ARCH Venture Partners. Source: Focus on Japanese science and innovations, a significant scientific arbitrage opportunity Build: Maximize value creation and capture by building companies in the top global ecosystem for biotech Finance: Syndicate with top global venture investors to maximize success, and bring attention to Japanese science

AdBio partners (formerly Advent France Biotechnology) is a venture capital firm investing in early stage life sciences companies in Europe. AdBio partners’ unique strategy combines early-stage investments in promising startups and strong entrepreneurial support to enable and strengthen the company’s growth. As an early-stage investor, we act as a catalyst to create companies based on innovations coming from academic research. We have established relationships with leading research institutions and technology transfer offices in Europe and benefit from the support of strong network of scientific, clinical, industry and financial partners. The operational team is managed by Alain Huriez, MD, Chairman and Managing Partner, and Geoffroy de Ribains, Managing Partner. The team includes seasoned investment professionals with long-standing track records in entrepreneurial ventures, combined with strong scientific, medical and operational expertise.

Our Ventures team supports the launch of startups based on University of Michigan technologies and research discoveries. We provide a full suite of resources, services and funding to help you launch sustainable, impactful world changing startups. The Ventures team will engage with you from day one to establish clear and executable commercialization, business formation and funding strategies. As your startup project begins to take form we can provide grant funding and investment capital, as well as business know-how, talent resources and connections to a nationwide network of investors. Whether it is helping you find the perfect team member, investment partner or connecting you with service providers, we have you covered.

We have invested in more than 90 companies since 2016, including Pinterest, Compass, Hippo, Ro, Carta, Dutchie, Anduril, Varda Space Industries, Ghost, Front, Esusu, OKCredit, and Unqork. Additionally, through our subsidiary fund, New Slate Ventures, we have financed films, documentaries, and limited series that have been acquired by Apple, Netflix, and Disney. Based in New York City, we invest globally. Backstory Sinai Capital Partners was founded in 2017. We raised $100 million and built a talented team of young investors with offices in New York, Palo Alto, and Los Angeles. We made over 90 investments, realized 11 exits, and achieved a 1X return on our first fund within two years. In 2019, we raised $100 million for a subsidiary of Sinai Capital called New Slate Ventures, with the goal of supplying the many players in the streaming wars with independent content. Our films, series, and documentaries won Academy Award nominations, Golden Globes, Grammy’s, and Emmy’s, and were acquired by the likes of Apple, Disney, and Netflix for multiples of their cost. As a solo GP, I believe boutique, disciplined, early-stage funds with effective managers will generate the best returns for investors in this forthcoming innovation cycle. Throughout my career I’ve nurtured relationships across Silicon Valley, Wall Street, Washington DC, and Hollywood, and aim to leverage this access on behalf of the founders I support. Where to Now? We’re currently in the midst of the greatest acceleration of technological progress since 2010 and the advent of mobile/social computing. New frameworks for problem solving are emerging daily aided by artificial intelligence, CRISPR technologies, climate manipulation, and several other radical new fields previously dismissed as science fiction. When we started Sinai, the prevailing wisdom in Silicon Valley was that “hardware was hard” and that software investments provided much better risk-adjusted opportunities. That assumption is becoming less credible in the current venture capital landscape, with space exploration, brain computer interfaces, driverless electric vehicles, autonomous warfare drones, and nuclear fusion companies all appearing to be increasingly within reach, with potentially transformational impacts on civilization. Sinai’s new focus will be on these harder technical problems, as we believe this is where the majority of the value creation for this next venture cycle will emerge. While we still welcome revenue generating SaaS businesses, its become clearer to us that the best returns come from the most non-obvious ideas in undefined markets and categories. Some of our latest investments include Anduril, Varda, Galvanick, Rangeview, Factory.AI, Science.IO, and several others. We seek to invest in 5-10 companies each year, with average check sizes ranging between $1-5M depending on stage. We’re happy to lead seed rounds where we have high conviction, but prefer to collaborate with our friends at top funds across the globe. We are geographically agnostic, but are most active in New York, San Francisco, Miami, London, and the South Bay of Los Angeles.

A C2 Capital Partners é uma sociedade de capital de risco independente, registada na Comissão de Mercado de Valores Mobiliários (CMVM), fundada em 2009 pela equipa de gestão (como Capital Criativo), sendo atualmente um operador de referência no setor de capital de risco em Portugal. A C2 tem duas áreas de negócio principais, tendo equipas de gestão dedicadas e autónomas para cada uma dessas áreas: Capital de Expansão e Investimentos Alternativos. Who2 A equipa C2 é composta por um conjunto de profissionais com track record reconhecido e vasta experiência nos setores de capital de risco, corporate finance, consultoria e gestão de empresas. What2 A C2 Capital Partners, como afiliada da Gaw Capital Partners, investe mais do que capital em empresas do seu portefólio. Os membros da equipa da C2 Capital Partners dedicam toda a sua energia, experiência e empenho para apoiar o crescimento do negócio das empresas em carteira. A Gaw Capital Partners é uma empresa de gestão de fundos de capital de risco com uma posição única, centrada nos mercados imobiliários a nível mundial. Especializada em acrescentar valor estratégico a imóveis subutilizados através de redesenho e reposicionamento, os investimentos da empresa abrangem todo o espetro de sectores imobiliários com as suas próprias plataformas operacionais de gestão de activos em parques comerciais, de retalho, residenciais, hoteleiros, de promoção imobiliária, logísticos, de IDC e de ciências da vida. Para além de Portugal, a Gaw Capital tem escritórios em 15 locais, incluindo Hong Kong, Singapura, Xangai, Tóquio, Seul, Los Angeles, São Francisco e Londres. Para além do investimento imobiliário, a Gaw Capital Partners também investe num portfólio diversificado de empresas em vários sectores verticais de risco, imobiliário / PropTech e em várias geografias. O Gaw Growth Equity Fund investe principalmente numa carteira de activos tangíveis no sector ESG e das energias limpas/renováveis, incluindo energia solar, eólica, baterias, reciclagem, processamento de biocombustíveis, conversão de biomassa e outras instalações comerciais e industriais, optimizando simultaneamente a diversificação, a estabilidade da distribuição, a cobertura da inflação e a atenuação da volatilidade. Desde 2005, a Gaw Capital levantou sete fundos mistos destinados às regiões da APAC. A empresa também gere fundos de valor acrescentado/oportunistas nos EUA, um fundo pan-asiático de hotelaria, um fundo europeu de hotelaria e um fundo de acções de crescimento, e também presta serviços para investimentos de crédito e investimentos directos em contas separadas a nível mundial. A Gaw Capital angariou capitais próprios no valor de 23 mil milhões de dólares desde 2005 e conta com activos de 36 mil milhões de dólares sob gestão no primeiro trimestre de 2023.